Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.

Clin Mol Hepatol · 2021 · PMC8046624 · PMID 33517606

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

At a median follow-up of 7 years, none of the immune-tolerant patients with FIB-4 <1.45 developed HCC, as compared to a cumulative HCC incidence of 1.4% at 5 years among treated patients with FIB-4 <1.45, though the difference between the two groups did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.